Navigation Links
Juventas Therapeutics Hires Biotechnology Veteran Paul Resnick as Vice President of Business Development
Date:1/28/2013

potential for JVS-100, we believe having someone with Paul's experience focused on strategic opportunities will allow us to best recognize the long-term value of this platform."

"I'm thrilled to join the Juventas team," remarked Dr. Resnick.  "Juventas is pursuing a unique therapeutic strategy in the exciting field of regenerative medicine.  Through activation of a patient's own stem-cell repair processes, JVS-100 delivers regenerative benefits without the cost and complexities typically associated with cell-based therapeutics.  I look forward to applying my industry perspective and leveraging my contacts to help Juventas transition toward commercialization."

About Juventas Therapeutics

Juventas Therapeutics, headquartered in Cleveland, OH, is a privately held clinical-stage biotechnology company developing a pipeline of regenerative therapies to treat life–threatening diseases. Founded in 2007 with an exclusive license from Cleveland Clinic, Juventas has transitioned its therapeutic platform from concept to initiation of mid-stage clinical trials for treatment of heart failure and critical limb ischemia.  Investors include Triathlon Medical Ventures, New Science Ventures, Takeda Ventures, Venture Investors, Early Stage Partners, Fletcher Spaght Ventures, Reservoir Venture Partners, Glengary, The Global Cardiovascular Innovation Center, Tri-State Growth Fund, North Coast Angel Fund, X Gen Ltd., JumpStart Inc., and Blue Chip Venture Co. The company has received non-dilutive grant support through the Ohio Third Frontier-funded Cleveland Clinic Ohio BioValidation Fund, Global Cardiovascular Innovation Center and Center for Stem Cell & Regenerative Medicine.


'/>"/>
SOURCE Juventas Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Juventas Therapeutics Raises $22.2 Million Series B Financing
2. Convoy Therapeutics Announces the Relaunch of Their Interactive Website
3. Shield Therapeutics Selects OpenClinica Enterprise
4. Cell Therapeutics, Inc.s (CTI) Board of Directors Approves Amendment of Shareholder Rights Plan
5. Stemline Therapeutics, Inc. Announces Presentations of SL-401 Updated Clinical Trial Results in Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) and SL-101 Preclinical Efficacy Data Against Hodgkins Lymphoma at
6. NKT Therapeutics Presents Data on Potential Antibody Treatment for Sickle Cell Disease
7. Cell Therapeutics Reports on Cooperative Group Sponsored Trial of Brostallicin in Patients with Metastatic Triple-Negative Breast Cancer
8. Smith & Nephew Announces Agreement To Acquire Assets Of Healthpoint Biotherapeutics
9. Intarcia Therapeutics Secures Landmark $210 Million Financing To Fund Its Global Phase 3 Program For ITCA 650 In Type 2 Diabetes
10. Karyopharm Therapeutics Announces Oral Presentation at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in preclinical models of Systemic Lupus Erythematosus (SLE)
11. Cell Therapeutics, Inc. (CTI) to Present at Jefferies 2012 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 Guggenheim Securities, the ... today announced the hiring of veteran equity analyst Charles ... analyst. Mr. Butler will focus on the biotech/biopharma sector. ... a wealth of experience and a broad network of ... Senior Managing Director and Head of Equities at Guggenheim ...
(Date:8/27/2014)... 27, 2014  ARCH Venture Partners, one of ... the development of seed and early-stage advanced technology ... closed with more than $400 million in subscriptions. ... subscription target by more than $150 million. ... strength and potential of our approach to finding ...
(Date:8/27/2014)... OR (PRWEB) August 27, 2014 According ... “Consolidation continues to reshape the look and feel of ... Consumer demand for higher-quality ingredients will push for more ... American market have experienced strong market growth in the ... attributes in their food and cosmetics to fit a ...
(Date:8/26/2014)... 26, 2014  NeuroSigma, Inc., a Los ... bioelectronic technologies, today announced that it has filed a ... and Exchange Commission relating to a proposed initial public ... to be offered and the price range for the ... Jefferies LLC will act as the book-running manager for ...
Breaking Biology Technology:Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 2Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 3
... Greater Baltimore,Committee is seeking nominations for the Third ... on Tuesday, March 18, 2008. Those,interested in nominating ... http://www.gbc.org ., The four award categories are: ... and President,s Award. Nominators will,be asked to submit ...
... Jan. 14 VIRxSYS Corporation, a,privately held company ... Lentigen Corporation, a privately-owned biotechnology company,focused on the ... they have agreed to settle the pending litigation ... claims and counterclaims,asserted in the lawsuit, which has ...
... Company Accelerating Efforts to Commercialize Bio-Based Technologies to ... ... DuPont (NYSE: DD ),has named Nicholas C. Fanandakis group ... Fanandakis will lead the,company,s accelerated efforts to commercialize a range ...
Cached Biology Technology:VIRxSYS and Lentigen Announce Litigation Settlement 2DuPont Names Nicholas Fanandakis as Group Vice President - DuPont Applied BioSciences 2
(Date:8/27/2014)... beasts. But every creature is a baby once. , ... of 24 very young dinosaurs and one older individual ... a caretaker, according to a new study by University ... Peter Dodson led the work, collaborating with researchers from ... is held. Hedrick is a doctoral student in the ...
(Date:8/27/2014)... rare, but deadly disease that exists as five strains, ... most lethal strains is the Sudan ebolavirus (SUDV). Although ... caused widespread illness, even as recently as 2012. In ... Chemical Biology , researchers now report a possible therapy ... , John Dye, Sachdev Sidhu, Jonathan Lai and colleagues ...
(Date:8/27/2014)... the long-standing belief that a deficiency in serotonin ... central role in depression. In the journal ACS ... ability to make serotonin in their brains (and thus ... show depression-like symptoms. , Donald Kuhn and colleagues ... Wayne State University School of Medicine note that depression ...
Breaking Biology News(10 mins):Penn paleontologists describe a possible dinosaur nest and young 'babysitter' 2Penn paleontologists describe a possible dinosaur nest and young 'babysitter' 3Potential therapy for the Sudan strain of Ebola could help contain some future outbreaks 2New study throws into question long-held belief about depression 2
... a gene for a specific protein face a 20-fold greater ... in mBio , the online open-access journal of the ... is the most common cause of fungal meningitis among HIV-infected ... HIV who has a very low level of CD4+ T ...
... at the Medical College of Wisconsin (MCW) have developed ... identify genetic mutations responsible for cancers.The tool, called DrGaP, ... the American Journal of Human Genetics . ... National Cancer Institute, and a former visiting scholar at ...
... FASEB MARC (Maximizing Access to Research Careers) Program ... Writing Seminar and Practical Exercises Workshop at the Marine ... 2012. Awards are given to graduate students, postdocs and ... have never written a successful grant application. This year ...
Cached Biology News:Gene makes some HIV-infected patients more at risk for fungal disease 2Gene makes some HIV-infected patients more at risk for fungal disease 3
Request Info...
... Nuclease catalyzes the degradation of single-stranded DNA ... products. While the nuclease prefers ssDNA over ... the enzyme degrades double-stranded DNA from both ... used for transcript mapping studies (3,4), for ...
... fosmid (40kb), and large plasmid insert (10-20kb) ... BAC vector. On command 20-50 fold copy ... DNA purification. Available with blue-white screening (pEZ ... the highest insert stability. Kits include electrocompetent ...
...
Biology Products: